FDA approves first drug for severe liver disease

FDA APPROVED resmetirom (Rezdiffra) over a computer rendering of a transparent body with the liver highlighted.

The FDA granted accelerated approval to resmetirom (Rezdiffra) as a first-line treatment for adults with noncirrhotic nonalcoholic steatohepatitis (NASH), also called metabolic dysfunction-associated steatohepatitis (MASH). A once-daily oral agent, resmetirom …

Read more